Cargando…
ESR1 fusions and therapeutic resistance in metastatic breast cancer
Breast cancer is the most frequent female malignant tumor, and the leading cause of cancer death in women worldwide. The most common subtype of breast cancer is hormone receptor positive that expresses the estrogen receptor (ER). Targeting ER with endocrine therapy (ET) is the current standard of ca...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9848494/ https://www.ncbi.nlm.nih.gov/pubmed/36686845 http://dx.doi.org/10.3389/fonc.2022.1037531 |